Tenofovir disoproxil fumarate (Viread, Gilead), an oral medication that inhibits retroviral replication, could have a new life as a convenient vaginal gel, say researchers from Harlem Hospital Center, Bronx-Lebanon Hospital/Center, University of Pennsylvania, and Miriam Hospital in Providence, Rhode Island.
In the first phase 1 clinical trial to evaluate an antiretroviral agent as a vaginal microbicide, [...]
A methylphenidate transdermal system (Daytrana, Shire) offers another option for children six to 12 years of age with Attention Deficit Hyperactivity Disorder (ADHD). This is the first non-oral medication for ADHD.
The patch, in strengths of 10, 15, 20 and 30 mg, is designed to be worn during a child’s normal daily activities. It should be [...]
Pramipexole dihydrochloride tablets (Mirapex, Boehringer Ingelheim) has been approved for the treatment of moderate-to-severe primary restless legs syndrome (RLS). RLS is a common neurological sensorimotor disorder. Patients typically describe an urge to move the legs, and they may experience burning, creeping, crawling, aching, tingling, or tugging sensations in the legs. Up to 10% of adults [...]
Refrigerated FluMist live intranasal influenza virus vaccine (Medlmmune) has been approved. The vaccine is used to prevent influenza in healthy children and adolescents 5 to 17 years of age and in healthy adults 18 to 49 years of age.
The new formulation, called CAIV-T (cold-adapted influenza vaccine-trivalent), can be stored in a refrigerator rather than in [...]
The FDA has approved a New Drug Application (NDA) supplement to add intravenous (IV) use as a new route of administration for azacitidine (Vidaza, Pharmion). This agent, which is indicated for the treatment of myelodys-plastic syndromes (MDS), may now be infused over a period of 10 to 40 minutes in a clinic or hospital setting.
IV [...]
Ortho Biotech’s combination of doxorubicin HCl liposome injection (Doxil) plus bortezomib (Velcade) has been approved to treat patients with multiple myeloma who have not previously received Velcade and who have received at least one previous therapy.
In an international phase 3 trial, the combination, compared with bortezomib alone, significantly extended the median time to disease progression [...]
Boston Scientific Corp. has completed enrollment of more than 23,000 patients in the European and Intercontinental phases (2 and 3) of its Taxus Olympia registry. The registry is designed to evaluate the safety and performance of its second-generation drug-eluting coronary stent, Taxus Liberte, in a real-world setting. Olympia is the world’s largest drug-eluting stent registry. [...]
